Simplex Trading
SYRE icon

Simplex Trading’s Spyre Therapeutics SYRE Stock Holding History

Simplex Trading’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-33,000
Closed -$1.08M – 10124
2025
Q4 		$1.08M Buy
33,000
+22,700
+220% +$593K ﹤0.01% 2555
2025
Q3 		$172K Buy
10,300
+10,200
+10,200% +$166K ﹤0.01% 5129
2025
Q2 		$1K Sell
100
-1,000
-91% -$14.8K ﹤0.01% 8436
2025
Q1 		$17K Buy
+1,100
New +$22.9K ﹤0.01% 6723
2022
Q2 		– Sell
-36
Closed -$2K – 11067
2022
Q1 		$2K Sell
36
-112
-76% -$9.4K ﹤0.01% 9934
2021
Q4 		$17K Buy
148
+92
+164% +$14.5K ﹤0.01% 8565
2021
Q3 		$9K Hold
56
– – ﹤0.01% 9008
2021
Q2 		$9K Buy
+56
New +$10.2K ﹤0.01% 9173
2021
Q1 		– Hold
0
– – – 8397
2019
Q4 		– Sell
-1
Closed -$19K – 7949
2019
Q3 		$19K Buy
+1
New +$195 ﹤0.01% 5852

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Simplex Trading's SYRE Position: Q3 2025 in Review

Simplex Trading sold out of Spyre Therapeutics (SYRE) in Q3 2025, closing a stake of 145 shares — an estimated $2.36K sold.

Simplex Trading first reported a position in SYRE in Q2 2019 and held it in 15 quarters. The position peaked at $14K in Q2 2019. 137 funds tracked by Wall St. Rank hold SYRE as of Q3 2025.

  • Simplex Trading reported no remaining Spyre Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Simplex Trading sold 145 Spyre Therapeutics shares in Q3 2025, an estimated $2.36K.
  • Simplex Trading first reported a position in Spyre Therapeutics in Q2 2019 and held it in 15 quarters.
  • Simplex Trading's Spyre Therapeutics position peaked at $14K in Q2 2019.
  • 137 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q3 2025.

Based on Simplex Trading's 13F filing for Q3 2025, filed 12 Nov 2025.